Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

Overview of attention for article published in Journal of Hematology & Oncology, June 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

So far, Altmetric has seen 5 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 1 additional patents.